News

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...
GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...
UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...
British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...
GSK ( NYSE: GSK) CEO Emma Walmsley said on Wednesday that her company is in discussions with the Trump administration on how ...
CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...
GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...
Its second-quarter sales rose to 7.99 billion pounds from 7.88 billion pounds in the same period the year prior.
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...
GSK anticipates high sales and profit growth in 2025 after surpassing second-quarter forecasts, while addressing U.S. tariffs ...
GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through ...